Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Stanislovas S Jankauskas, Paola Gallo, Francesco Rozza, Giuseppe Giugliano, Alessandra Spinelli, Giovanni Esposito, Roberto Piccinocchi, Gaetano Piccinocchi, Carmine Morisco, Maria Lembo, Gaetano Santulli, Bruno Trimarco
{"title":"阿司匹林可降低与COVID-19相关的2型糖尿病的风险。","authors":"Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Stanislovas S Jankauskas, Paola Gallo, Francesco Rozza, Giuseppe Giugliano, Alessandra Spinelli, Giovanni Esposito, Roberto Piccinocchi, Gaetano Piccinocchi, Carmine Morisco, Maria Lembo, Gaetano Santulli, Bruno Trimarco","doi":"10.1038/s44324-025-00072-3","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"27"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177057/pdf/","citationCount":"0","resultStr":"{\"title\":\"Aspirin reduces the risk of type 2 diabetes associated with COVID-19.\",\"authors\":\"Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Stanislovas S Jankauskas, Paola Gallo, Francesco Rozza, Giuseppe Giugliano, Alessandra Spinelli, Giovanni Esposito, Roberto Piccinocchi, Gaetano Piccinocchi, Carmine Morisco, Maria Lembo, Gaetano Santulli, Bruno Trimarco\",\"doi\":\"10.1038/s44324-025-00072-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.</p>\",\"PeriodicalId\":501710,\"journal\":{\"name\":\"npj Metabolic Health and Disease\",\"volume\":\"3 1\",\"pages\":\"27\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177057/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"npj Metabolic Health and Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/s44324-025-00072-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj Metabolic Health and Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s44324-025-00072-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Aspirin reduces the risk of type 2 diabetes associated with COVID-19.
This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
